Back to Top

Journal for ImmunoTherapy of Cancer (JITC)

Publisher :

BMJ Publishing Group

  • Pharmacology
  • Toxicology
  • Pharmaceutics
  • +4

e-ISSN :

2051-1426

Issue Frequency :

Continuously

Impact Factor :

10.9

Est. Year :

2024

Mobile :

12678951758

Country :

United States

Language:

English

APC :

YES

Email :

info.jitc@bmj.com

Journal Descriptions

The Journal for ImmunoTherapy of Cancer (JITC) is an open access, peer-reviewed journal that aims to enrich communication and advance scientific understanding in the rapidly evolving fields of tumor immunology and cancer immunotherapy. Topics of interest range across the basic science-translational-clinical spectrum and include tumor-host interactions, the tumor microenvironment, animal models, predictive and prognostic immune biomarkers, novel pharmaceutical and cellular therapies, vaccines, combination immune-based therapies, and immune-related toxicity. The Journal for ImmunoTherapy of Cancer is an open access journal that publishes high quality research, literature reviews, position papers and practice guidelines, and case studies on all components of cancer immunology and immunotherapy.


Journal for ImmunoTherapy of Cancer (JITC) is :

International, Peer-Reviewed, Open Access, Refereed, Pharmacology, Toxicology, Pharmaceutics, Immunology, Allergy, Oncology, Microbiology , Online Continuously Journal

UGC Approved, ISSN Approved: P-ISSN , E-ISSN - 2051-1426, Established in - 2024, Impact Factor - 10.9

Not Provide Crossref DOI

Indexed in Scopus, DOAJ

Not indexed in WoS, PubMed, UGC CARE

Indexing

+1 More

Scopus Profile
Peer reviewed only
Scopus Profile
Open access journal

Establish Your Own Journal Without the Expense!

OJSCloud offers a complete, free setup to get you publishing.

Start Your Free Journal!
free profile